Clicky

Apexigen, Inc.(APGN)

Description: Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Biology Immunology Antibodies Cancer Immunotherapy Antibody Monoclonal Antibody Antibody Solutions

Home Page: www.apexigen.com

APGN Technical Analysis

75 Shoreway Road
San Carlos, CA 94070
United States
Phone: 650-931-6236


Officers

Name Title
Dr. Xiaodong Yang M.D., Ph.D. Pres, CEO & Director
Ms. Amy Wong Sr. VP of Fin. & Operations
Dr. Frank J. Hsu M.D. Chief Medical Officer
Mr. William E. Duke Jr. Chief Financial Officer
Mr. Francis W. Sarena Chief Operating Officer
Dr. Jason Wright Ph.D. Sr. VP of CMC

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.3187
Price-to-Sales TTM: 0
IPO Date: 2021-02-22
Fiscal Year End: December
Full Time Employees: 22
Back to stocks